Alto Neuroscience reports ~$244.2M cash; plans additional Phase 3 trial for ALTO-207

Alto Neuroscience, Inc.

Preliminary cash, cash equivalents and restricted cash of ~$244.2M as of June 30, 2026 (unaudited).
Company intends to accelerate ALTO-207 development, including an additional Phase 3 monotherapy trial for treatment-resistant depression.
No other financial results or guidance provided in this filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.